Scope Fluidics

Scope Fluidics Liabilities

The The Liabilities of Scope Fluidics (SCP.WA) as of Oct 24, 2026 is 33.50 M PLN. In the previous year, The Liabilities was 26.52 M PLN — a change of 26.34% (higher).

Liabilities

33.50 MPLN

YoY

26.34%

Last updated:

In 2025, Scope Fluidics's total liabilities amounted to 33.50 M PLN, a 26.34% difference from the 26.52 M PLN total liabilities in the previous year.

The Scope Fluidics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.10 M PLN
Jan 1, 2019
7.19 M PLN
Jan 1, 2020
8.22 M PLN
Jan 1, 2021
38.15 M PLN
Jan 1, 2022
13.18 M PLN
Jan 1, 2023
20.56 M PLN
Jan 1, 2024
26.52 M PLN
Jan 1, 2025
33.50 M PLN
The Scope Fluidics Liabilities history
YEARLiabilitiesYoY
33.50 MPLN+26.34%
26.52 MPLN+28.99%
20.56 MPLN+55.96%
13.18 MPLN-65.45%
38.15 MPLN+364.13%
8.22 MPLN+14.39%
7.19 MPLN+552.49%
1.10 MPLN-39.28%
1.81 MPLN+103.45%
891,520.00PLN-67.80%
2.77 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Scope Fluidics's Liabilities

Scope Fluidics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Scope Fluidics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Scope Fluidics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Scope Fluidics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Scope Fluidics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Scope Fluidics stock

The Liabilities of Scope Fluidics is 33.50 M PLN in 2025.

The Liabilities of Scope Fluidics changed from 26.52 M PLN to 33.50 M PLN, representing a 26.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Scope Fluidics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Scope Fluidics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Scope Fluidics